197 related articles for article (PubMed ID: 33961011)
1. Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort.
Combe B; Rincheval N; Berenbaum F; Boumier P; Cantagrel A; Dieude P; Dougados M; Fautrel B; Flipo RM; Goupille P; Mariette X; Saraux A; Schaeverbeke T; Sibilia J; Vittecoq O; Daurès JP
Rheumatology (Oxford); 2021 Nov; 60(11):5073-5079. PubMed ID: 33961011
[TBL] [Abstract][Full Text] [Related]
2. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
[TBL] [Abstract][Full Text] [Related]
3. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.
Combe B; Logeart I; Belkacemi MC; Dadoun S; Schaeverbeke T; Daurès JP; Dougados M
Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions.
Castrejón I; Dougados M; Combe B; Fautrel B; Guillemin F; Pincus T
J Rheumatol; 2016 Jul; 43(7):1285-91. PubMed ID: 27084913
[TBL] [Abstract][Full Text] [Related]
6. Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort.
Mouterde G; Rincheval N; Lukas C; Daien C; Saraux A; Dieudé P; Morel J; Combe B
Arthritis Res Ther; 2019 Jun; 21(1):140. PubMed ID: 31171038
[TBL] [Abstract][Full Text] [Related]
7. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
8. Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes.
Ruyssen-Witrand A; Guernec G; Nigon D; Tobon G; Jamard B; Rat AC; Vittecoq O; Cantagrel A; Constantin A
Ann Rheum Dis; 2015 Sep; 74(9):1676-83. PubMed ID: 24794151
[TBL] [Abstract][Full Text] [Related]
9. The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort.
Durán J; Combe B; Niu J; Rincheval N; Gaujoux-Viala C; Felson DT
Rheumatology (Oxford); 2015 Dec; 54(12):2166-70. PubMed ID: 26175470
[TBL] [Abstract][Full Text] [Related]
10. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.
van Nies JA; Tsonaka R; Gaujoux-Viala C; Fautrel B; van der Helm-van Mil AH
Ann Rheum Dis; 2015 May; 74(5):806-12. PubMed ID: 25561360
[TBL] [Abstract][Full Text] [Related]
11. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.
Ajeganova S; van Steenbergen HW; van Nies JA; Burgers LE; Huizinga TW; van der Helm-van Mil AH
Ann Rheum Dis; 2016 May; 75(5):867-73. PubMed ID: 25972519
[TBL] [Abstract][Full Text] [Related]
12. Does the presence of magnetic resonance imaging-detected osteitis at diagnosis with rheumatoid arthritis lower the risk for achieving disease-modifying antirheumatic drug-free sustained remission: results of a longitudinal study.
Burgers LE; Boeters DM; Reijnierse M; van der Helm-van Mil AHM
Arthritis Res Ther; 2018 Apr; 20(1):68. PubMed ID: 29636084
[TBL] [Abstract][Full Text] [Related]
13. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry.
Martin WJ; Shim M; Paulus HE; Chaudhari S; Feng J; Elashoff D; Hahn TJ; Ranganath VK;
J Clin Rheumatol; 2014 Sep; 20(6):301-5. PubMed ID: 25160011
[TBL] [Abstract][Full Text] [Related]
14. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
Boeters DM; Burgers LE; Toes RE; van der Helm-van Mil A
Ann Rheum Dis; 2019 Nov; 78(11):1497-1504. PubMed ID: 31413004
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
[TBL] [Abstract][Full Text] [Related]
16. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis.
Ranganath VK; Maranian P; Elashoff DA; Woodworth T; Khanna D; Hahn T; Sarkisian C; Kremer JM; Furst DE; Paulus HE
Rheumatology (Oxford); 2013 Oct; 52(10):1809-17. PubMed ID: 23813577
[TBL] [Abstract][Full Text] [Related]
17. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort.
Khanna D; Oh M; Furst DE; Ranganath V; Gold RH; Sharp JT; Park GS; Keystone EC; Paulus HE;
Arthritis Rheum; 2007 Apr; 57(3):440-7. PubMed ID: 17394230
[TBL] [Abstract][Full Text] [Related]
19. In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study.
Fanouriakis A; Papalopoulos I; Gergianaki I; Spyrou G; Erden A; Rapsomaniki P; Terizaki M; Avgoustidis N; Repa A; Kougkas N; Bertsias G; Boumpas DT; Sidiropoulos PI
Clin Exp Rheumatol; 2018; 36(5):806-813. PubMed ID: 29533750
[TBL] [Abstract][Full Text] [Related]
20. Effect of age at rheumatoid arthritis onset on clinical, radiographic, and functional outcomes: The ESPOIR cohort.
Krams T; Ruyssen-Witrand A; Nigon D; Degboe Y; Tobon G; Fautrel B; Berenbaum F; Cantagrel A; Constantin A
Joint Bone Spine; 2016 Oct; 83(5):511-5. PubMed ID: 26992954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
